Overview
CRIS market data
Price History
CRIS price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for CRIS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Curis Gains As Blood Cancer Drug Progresses, December Readout in FocusBenzinga · Jul 24, 2026, 6:03 PM
Curis shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $17 to $43.Benzinga · Jul 24, 2026, 3:21 PM
HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $43Benzinga · Jul 24, 2026, 10:14 AM
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response RatesBenzinga · Jul 22, 2026, 5:04 PM
Curis To Announce Positive Updates On Emavusertib Studies For Lymphoma And Lymphociytic Leukemia July 22Benzinga · Jul 22, 2026, 11:12 AM
Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 13, 2026, 8:39 AM
Curis Announces It Has Consented The First Six Patients In The TakeAim CLL StudyBenzinga · Jul 6, 2026, 1:35 PM
8-K filing — CURIS INC (CRIS)SEC EDGAR · Jul 2, 2026, 12:56 PM
8-K/A filing — CURIS INC (CRIS)SEC EDGAR · Jul 1, 2026, 3:22 PM
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving PremarketBenzinga · Jun 29, 2026, 11:05 AM